

Instructions for Contributors to Translational Oncology 2011

Scope and Mission

Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

Peer Review

The Editors are committed to a rapid review process with high quality standards. Every effort will be made to obtain reviews and return editorial decisions to the authors within 3 weeks of manuscript receipt. When manuscripts are accepted contingent on revision, the revised work must be received within three months of the decision date, unless prior arrangements are made with the Editors.

Guidelines for Editorial Decisions

The primary criteria for judging which manuscripts are published are originality and scientific/clinical significance. Manuscripts may be editorially declined on these grounds, even if the experimental work appears technically sound.

Manuscript Submission

For rapid processing, Translational Oncology requires that submissions be made ONLINE through the JournalSoft system. The authors must sign the Manuscript Warranty and Copyright Assignment form online, at the end of their submission process.

Submission Address

Theodore S. Lawrence, Ph.D. M.D., Editor
Translational Oncology Editorial Office
University of Michigan Medical Center
109 Zina Pitcher Place, BSRB A628
Ann Arbor, MI 48109
Tel.: (734) 647-6679; Fax: (734) 615-5669

Prior Publication

The submitted material must not be published nor submitted elsewhere, except in abstract form.

Conflict of Interest

Authors should disclose any commercial affiliations or financial interests that may be considered conflicts of interest regarding the submitted manuscript. This information should be provided in the Acknowledgements section.

Manuscript Categories

Translational Oncology publishes Original Reports, Reviews and Editorials. Original Reports are full length original articles. Authors wishing to contribute a Review should contact the Editor. Reviews should focus on a recent development or issue in a single area, rather than attempt to exhaustively cover an entire topic.

Manuscript Style & Organization

Please begin each section on a new page. Line numbering is useful for review purposes; their use is left to the author's discretion.

Title Page: The title of the manuscript should be followed by complete names of all authors and their institutional affiliations. The name, mailing address, telephone number, fax number, and email address of the corresponding author should be provided. Furnish a running title of not more than 50 characters and spaces. Please furnish five (5) keywords describing the manuscript subject matter. Revised manuscripts should be so noted and include the original manuscript number.

Abstract: The abstract should not exceed 250 words, and summarize the materials, methods, results, and significant conclusions reported in the manuscript. Citations in the abstract must be given in full. On the same page, supply an alphabetical list of nonstandard abbreviations used in the paper three or more times, with their full definitions.

Introduction: A succinct presentation of the nature and scope of the problem investigated should be provided followed by a review of the pertinent literature, methodological approach, and principle results.

Materials and Methods: Provide enough detail so that someone familiar with the techniques could repeat the experiments. Subheadings should be used and when possible, correlate with those used in the Results section.

Results: It may be useful to give an overall description of the experiments without repeating experimental details. Strive to present the data with clarity avoiding redundancy.

Discussion: Present the relationships, generalizations and principles among the observed results and how your results agree (or contrast) with other published work. State and provide evidence for each conclusion.

Acknowledgements: Please recognize any individuals who contributed to the manuscript and list funding sources.

Figure Legends should be separated from the figures.

Tables: Please double-space tables on separate pages without vertical rules. Label each table with an Arabic numeral adjacent to its title.

References: References to published works should be cited parenthetically by number in the order in which they appear. Type references double-spaced, including all authors' names, year, complete article title, and inclusive page numbers. Abbreviate the names of journals using the standard MED-LINE abbreviations, which can be found at the National Center for Biotechnology Information Journal Browser web site (ftp://ftp.ncbi.nih.gov/pubmed/J_Entrez.txt). Citations such as "submitted for

publication,” or “personal communication,” should be included parenthetically in the text, not with the References. Written permission to use personal communications must be provided. Unpublished meeting abstracts should not be cited. An Endnote Style File for Automated References Section Generation is available at <http://www.transonc.com/authinst.php>

Journal Articles

- [1] Kirn DH, and McCormick F. Replicating viruses as selective cancer therapeutics. *Mol. Med. Today*. 1996; **2**: 519–527.
- [2] O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell*. 1997; **88**: 277–285.
- [3] In press: Authors listed as above (tentative publication date). Title of paper. *Journal Name*, In press.

Complete Books

- [4] Martin SJ (1997). *Apoptosis and Cancer*. Karger Landers, Basel, Switzerland.

Chapters in Books

- [5] Kastan ME (1997). *Molecular Biology of Cancer: The Cell Cycle*. In *Cancer: Principles and Practice of Oncology*. VT DiVita, Jr., S Hellman, and SA Rosenberg, Eds. Lippicott-Raven, Philadelphia, PA. pp. 121–134.

Published Abstracts

- [6] Pawelek JM, Low KB, and Bermudes D (1997). Tumor-targeted Salmonella as a novel anti-cancer vector. *Cancer Gene Ther.* **4**, p. S24.

Sequence Data

GenBank/EMBL/DBJ database accession numbers are required for all new sequences before they can be published in Translational Oncology. Sequence data should be sent to GenBank before the manuscript is submitted for review. If the number is not available at the time of submission, it can be added at the page-proof stage.

Figures

Labels & Sizes: Illustrations must be self-explanatory and cited in numerical order in the text. Arabic numerals should be used to label figures and upper-case letters should designate specific panels of a multiple-part figure (e.g., Figs. 1A and 3D). Submission of electronic figures is required in PDF format.

Manuscripts Accepted for Publication

Accepted manuscripts will be published rapidly after receipt of the final version. Authors can help to reduce the publication time of a manuscript by promptly returning corrected page proofs to the production office.

Copyediting and Production: Address inquiries to Donna Cox Customer Service Representative, SPI Publisher Services, 2807 North Parham Road, Suite 350, Richmond, Virginia 23294. Tel: (804)-237-0205; Fax: (703)-562-1858; Email: Donna.Cox@spi-global.com; Web site: <http://www.spi-global.com>.

Page Charges & Reprints. There is a flat charge of \$1800 per manuscript (up to 8 printed pages and \$200 for each additional page).

Payment must be made prior to publication.

Web Site: <http://www.TransOnc.com>

For Authors: The Translational Oncology website offers useful services for manuscript submission and tracking. Translational Oncology assigns a manuscript number and password to each submission that can be used at the Translational Oncology website to obtain the real-time status of the manuscript in the review and publication process. Electronic submission of manuscripts and figures is also supported.

For Reviewers: The review process for Translational Oncology is carried out electronically whenever possible. Reviewers are asked to transmit their reviews electronically by filling out the review forms found at the Translational Oncology web site.